Bioniq, which offers personalized nutritional support based on blood biomarker data, has announced that global soccer legend Cristiano Ronaldo has made a ‘significant investment in the company, bringing its total valuation to US$82 million.’
The latest (undisclosed) investment from Ronaldo follows the close of a US$15 million Series B funding round for Bioniq in July 2024.
The company has also reported that its total user base has grown more than 5x in 2024.
According to a company release… ‘As a Bioniq member since 2022 and a regular user of its personalized supplements for nearly three years, Ronaldo’s stake in the company not only underscores his commitment to optimizing health and performance, both on and off the field, but continues to signal vitamins, minerals, and supplements as a key emerging category for high performance athletes and consumers alike. Ronaldo will also participate in future brand and product innovation.’
Combining blood biomarker analysis and self-reported health data, Bioniq creates customized supplements designed to meet individual health needs.
“Backing Bioniq goes beyond just an investment opportunity for me – it’s about aligning with a shared vision for health, performance, and longevity,” said Cristiano Ronaldo.
“I have been using their products myself for almost three years. With their personalized health approach, I believe Bioniq has the potential to transform how we care for our bodies and help people reach and maintain their peak performance for longer.”
Ronaldo’s investment marks a pivotal moment for Bioniq as it accelerates international expansion with particular focus on the US, Europe, and the Middle East – with the US now contributing over 60% of total global sales.
“Cristiano Ronaldo is the perfect partner and shareholder,” said Vadim Fedotov, Co-Founder and CEO of Bioniq.
“As the ultimate embodiment of performance and longevity, Cristiano fully aligns with the values and mission of Bioniq. We are thrilled that the world’s leading athlete and advocate of a healthy lifestyle has made Bioniq part of his journey since 2022.
“His personal experience with our products reinforces his belief in what we’re building. Cristiano’s decision to invest, highlights his confidence in our team’s vision and his commitment to helping us build the leading company in personalized health.”
Bioniq claims to have built the largest proprietary biochemical database of its kind, leveraging blood test data from customers across five continents.
The AI-powered patent-pending Bioniq algorithm assesses an individual’s height, weight, age, lifestyle, and health goals to identify micronutrient imbalances and deliver nutritional insights, daily nutrient support, and 1:1 nutrition consultations and educational resources.
All of Bioniq’s supplements are Swiss-made, pharmaceutical-grade and utilize micro-dosing to address bio-individual needs and deficiencies. Each formula is created specifically for an individual user and features a unique mix of up to 120 antioxidants, vitamins, minerals, phytonutrients, amino acids and prebiotic fibre.
Rather than traditional pills and capsules, the product is delivered in patented prebiotic guar granules, which are designed to mimic the way the body digests food, minimizing nutrient competition and maximizing bioavailability.
www.bioniq.com